

**Table 2.** Anthropometric and densitometric evaluation according to the history of fractures

	<b>Unfractured (n = 16)</b> <b>Mean ± SD</b>	<b>Fractured (n = 8)</b> <b>Mean ± SD</b>	<b>p</b>
Age at diagnosis, years	8.8 ± 3.4	9 ± 2.5	0.878
Age at start GH therapy, years	9.2 ± 3.1	9.3 ± 2.5	0.759
Age at start HRT, years	13.5 ± 0.9 (n = 13)	13.1 ± 0.7	0.363
Duration of GH therapy, years	6.5 ± 2.8*	7.8 ± 2.7**	0.298
Duration of HRT, years	4.1 ± 1.9 (n = 13)	5.3 ± 1.7	0.103
Age at densitometric evaluation, years	16.9 ± 3.5	17.3 ± 2.3	0.927
Stature at densitometric evaluation, Z-score	-1.7 ± 0.9	-1.9 ± 0.6	0.539
BMI at densitometric evaluation, Z-score	0.8 ± 0.9	1.1 ± 0.9	0.623
Lumbar aBMD, Z-score	-1.1 ± 1.1	-1.5 ± 1.1	0.408
Lumbar vBMD, Z-score	-0.3 ± 0.9	-0.3 ± 1	0.951
Femoral aBMD, Z-score	-1.3 ± 0.5	-1.8 ± 1.3	0.230
Femoral vBMD, Z-score	-0.7 ± 0.7	-0.8 ± 1.6	0.644
AD-SoS, Z-score	-1.1 ± 1.3	-2.1 ± 0.6	0.021
BTT, Z-score	-1.4 ± 1.1	-2.4 ± 0.5	0.023

\* 8 girls had stopped GH therapy from 1.3 ± 0.6 years (range 0.1-2.1).

\*\* 7 girls had stopped GH therapy from 1.6 ± 0.8 years (range 0.6-2.5).